Capricor Therapeutics is trading 5.14% higher at $8.79, with no clear company-specific catalyst identified. - Broader U.S. markets were lower on September 28, 2026. Rising oil prices, Treasury yields and geopolitical concerns weighed on sentiment, but were not established as the reason for the stock’s gain. - HOPE-3 data presentations are scheduled for September 29–October 3; the company did not link them to the stock move.